Search Results for: Xenazine

Xenazine

Xenazine (tetrabenazine) is a medicine that Lundbeck Pharmaceuticals developed to treat one of the symptoms of Huntington’s disease known as chorea. Chorea refers to the involuntary and uncontrollable dance-like ... Read more

RNAi Therapies

Gene silencing by RNA interference (RNAi) is a therapeutic approach for the treatment of Huntington’s disease that is currently in development. The goal of this strategy is to reduce ... Read more

Treatments for Huntington’s disease

Huntington’s disease is a progressive neurodegenerative disorder, caused by inheritable mutations in the huntingtin (HTT) gene. The mutation produces a toxic form of the HTT protein that aggregates in ... Read more

Seroquel (Quetiapine)

Seroquel (quetiapine) is an antipsychotic medication marketed by AstraZeneca for the treatment of schizophrenia and bipolar disorder. It is also used along with antidepressants to treat depression. In Huntington’s ... Read more

Abilify (Aripiprazole)

Abilify (aripiprazole) is an antipsychotic medication manufactured by Otsuka and Bristol-Myers Squibb. It is approved by the U.S. Food and Drug Administration to treat psychiatric disorders such as schizophrenia. It ... Read more

Zyprexa (Olanzapine)

Zyprexa (olanzapine) is an antipsychotic medication, manufactured by Eli Lilly, and approved by the U.S. Food and Drug Administration (FDA) to treat schizophrenia, depression, and bipolar disorder. It may be ... Read more

VY-HTT01

VY-HTT01 is an investigational therapy to treat Huntington’s disease, being developed by Voyager Therapeutics, in collaboration with Sanofi-Genzyme and the CHDI Foundation. How VY-HTT01 works Huntington’s disease is a neurodegenerative disorder, caused ... Read more

SRX246

SRX246 is an investigational medication being developed by Azevan Pharmaceuticals to treat neuropsychiatric conditions. Now in the clinical testing stage, it is being investigated as a possible treatment for ... Read more

SOM3355

SOM3355 is an experimental treatment being developed by SOM Biotech to treat movement disorders in Huntington’s disease. SOM Biotech is currently seeking orphan drug status for SOM3355 from the U.S. Food and ... Read more